ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2988

Novel Use of Musculoskeletal Ultrasound (MSUS) to Measure Ulcers in the Skin of Systemic Sclerosis (SSc) Patients.

Yossra Suliman1,2, Veena K. Ranganath2, Suzanne Kafaja3 and Daniel E. Furst4, 1Rheumatology and Rehabilitation department, Assiut university, Faculty of Medicine,, Assiut, Egypt, 2Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, 3Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Systemic sclerosis, ulcers and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

1) To describe the role of MSUS, using both grey scale (GS) and Power Doppler (PD), to detect skin ulcers in SSc patients. 2) To look for initial indications that MSUS may be useful to guide therapy for SSc-ulcers.

Methods:

We examined a convenience sample of 7 SSc patients with skin ulcers by MSUS which  was performed using General Electric Logic E9 scanner using a 5-16 MHz linear array transducer.  PD settings: pulse repetition frequency 800 Hz, frequency 10 mHz and low wall filter. We proposed preliminary definitions of Ulcer characteristics based on normal skin reference (1). Pain and ulcer measures were obtained using 100 mm visual analogue scales (VAS).

Results:

 7 SSc patients met 2013 EULAR /ACR criteria for SSc. Median (range) for mRSS: 14 (9-25). 5 patients had diffuse SSc. The 7 patients had 16 clinically apparent skin ulcers. We categorized them on GS as a) skin ulcer (GS-SU); characterized by loss of skin thickness both epidermal and dermal layers, or loss of epidermal layer with irregular hyper-echoic granulation tissue below the level of the surrounding epidermis (figure 1a, b), b) Non-ulcer lesions (GS-NUL); show no loss of epidermal layer but show irregular hyper-echoic tissue at the same or above the level of epidermis (figure 1c).

Twelve GS-SU/NUL (75%) were on the PIPs, 2 (13%) on the legs, 1 (6%) on the DIP and 1(6%) on the elbow. Two ulcers in one patient demonstrated high PD signals (presumed underlying infection). After treatment for 15 days with Ciprofloxacin, PD signal was reduced, and both pain and ulcer VASs decreased from 100 mm to 40mm (fig 2a,b). Five lesions showed underlying calcinosis (3 of 5 lesions with calcinosis had evidence of positive PD signals). Variable ulcer depths and dimensions were detected. The highest pain and ulcer VASs (100mm) were recorded in the ulcers with the highest PD signal (table 1).

Conclusion:

This is the first study to show a  promising role of MSUS in evaluating skin ulcers in SSc patients. MSUS may have a role in identifying depth and underlying pathology (i.e. infection and calcinosis) of the lesion. Hence, MSUS can add clinical information and help in guiding treatment. Future studies are warranted with more SSc patients to further validate our preliminary findings.

Ref (1)Wortsman X. Sonography of Cutaneous and Ungual Lumps and Bumps Ultrasound Clin 7 (2012) 505–523


Disclosure: Y. Suliman, None; V. K. Ranganath, Genentech and Biogen IDEC Inc., 2,Pfizer Inc, 2,Bristol-Myers Squibb, 2,Bristol-Myers Squibb, 5; S. Kafaja, None; D. E. Furst, Gilead, 2,GlaxoSmithKline, 2,NIH, 2,Novartis Pharmaceutical Corporation, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2,Genentech and Biogen IDEC Inc., 2,UCB, 2,Abbvie, 5,Actelion Pharmaceuticals US, 5,Amgen, 5,Bristol-Myers Squibb, 5,Cytori, 5,Janssen Pharmaceutica Product, L.P., 5,Gilead, 5,GlaxoSmithKline, 5,NIH, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,Genentech and Biogen IDEC Inc., 5,UCB, 5,Abbvie, 8,Actelion Pharmaceuticals US, 8,Bristol-Myers Squibb, 2,Amgen, 2,Actelion Pharmaceuticals US, 2,Abbvie, 2,UCB, 8.

To cite this abstract in AMA style:

Suliman Y, Ranganath VK, Kafaja S, Furst DE. Novel Use of Musculoskeletal Ultrasound (MSUS) to Measure Ulcers in the Skin of Systemic Sclerosis (SSc) Patients. [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/novel-use-of-musculoskeletal-ultrasound-msus-to-measure-ulcers-in-the-skin-of-systemic-sclerosis-ssc-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-use-of-musculoskeletal-ultrasound-msus-to-measure-ulcers-in-the-skin-of-systemic-sclerosis-ssc-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology